文献速递妇科

PP2A与E3泛素连接酶缺陷:子宫内膜癌的关键生物学驱动因素

PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2021-04-16

研究纳入209例子宫内膜癌患者,排除POLE突变后分析PI3K-AKT通路相关基因变异与预后。发现PP2A和E3泛素连接酶缺陷与无进展生存期缩短显著相关,且独立于PIK3CA、PTEN、PIK3R1突变及PIK3CA拷贝数变异。

要点

  • PP2A缺陷和E3UL缺陷与PFS受损显著相关(P<.001)。
  • 84%复发患者存在PP2A和/或E3UL缺陷。
  • PP2A/E3UL缺陷独立于PIK3CA/PTEN/PIK3R1突变及PIK3CA CNV。

核心结论

  • PP2A和E3泛素连接酶缺陷是子宫内膜癌的关键生物学驱动因素,独立于PIK3CA、PTEN、PIK3R1突变及PIK3CA拷贝数变异。

研究设计与样本

  • 从TCGA子宫内膜癌队列中排除POLE突变患者,最终纳入209例子宫内膜样或浆液性子宫内膜癌患者,具备DNA测序、基因特异性RNA表达、拷贝数变异及监测数据。

主要发现

  • 83%患者存在PIK3CA、PTEN或PIK3R1突变;57%携带超过1个突变,未对PFS产生不利影响(P=.10)。
  • PIK3CA拷贝数变异≥1.1(CNV高)检出率为26%,与TP53突变和CIP2A表达相关(P<.001),但与PFS无关(P=.24)。
  • CIP2A高表达或PPP2R1A突变(PP2A缺陷)以及FBXW7突变(E3UL缺陷)与PFS受损相关(P<.001),并对PIK3CA突变和PIK3CA CNV高肿瘤具有预后区分价值(P<.001)。
  • 在有记录的复发中,84%与PP2A缺陷(75%)和/或E3UL缺陷(20%)相关。

临床怎么用

  • PP2A和E3UL缺陷状态可能作为子宫内膜癌的预后标志物,尤其对于PIK3CA突变或PIK3CA CNV高的肿瘤。

局限性

  • 研究排除了POLE突变患者,样本量有限(209例),且为回顾性队列分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: PI3K-AKT pathway mutations initiate a kinase cascade that characterizes endometrial cancer (EC). As kinases seldom cause oncogenic transformation without dysregulation of antagonistic phosphatases, pivotal interactions governing this pathway were explored and correlated with clinical outcomes. METHODS: After exclusion of patients with POLE mutations from The Cancer Genome Atlas EC cohort with endometrioid or serous EC, the study population was 209 patients with DNA sequencing, quantitative gene-specific RNA expression, copy number variation (CNV), and surveillance data available. Extracted data were annotated and integrated. RESULTS: A PIK3CA, PTEN, or PIK3R1 mutant (-mu) was present in 83% of patients; 57% harbored more than 1 mutation without adversely impacting progression-free survival (PFS) (P = .10). PIK3CA CNV of at least 1.1 (CNV high [-H]) was detected in 26% and linked to TP53-mu and CIP2A expression (P < .001) but was not associated with PFS (P = .24). PIK3CA expression was significantly different between those with CIP2A-H and CIP2A low (-L) expression (the endogenous inhibitor of protein phosphatase 2A [PP2A]), when stratified by PIK3CA mutational status or by PIK3CA CNV-H and CNV-L (all P < .01). CIP2A-H or PPP2R1A-mu mitigates PP2A kinase dephosphorylation, and FBXW7-mu nullifies E3 ubiquitin ligase (E3UL) oncoprotein degradation. CIP2A-H and PPP2R1A-mu (PP2A impairment) and FBXW7-mu (E3UL impairment) were associated with compromised PFS (P < .001) and were prognostically discriminatory for PIK3CA-mu and PIK3CA CNV-H tumors (P < .001). Among documented recurrences, 84% were associated with impaired PP2A (75%) and/or E3UL (20%). CONCLUSION: PP2A and E3UL deficiencies are seminal biological drivers in EC independent of PIK3CA-mu, PTEN-mu, and PIK3R1-mu and PIK3CA CNV.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Bosquet J, Bakkum-Gamez JN, Weaver AL, et al. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. Gynecol Oncol. 2021. PMID: 33867147. doi:10.1016/j.ygyno.2021.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。